# EDGAR Filing Document

**Accession Number:** 0001825413
**File Stem:** 0001213900-23-011557
**Filing Date:** 2023-2
**Character Count:** 2926
**Document Hash:** f85080520440d537547d834224614775
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-011557.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001213900-23-011557

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**EFFECTIVENESS DATE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biotech Acquisition Co
- **CENTRAL INDEX KEY:** 0001825413
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39935
- **FILM NUMBER:** 23630564

**BUSINESS ADDRESS:**
- **STREET 1:** 545 WEST 25TH STREET
- **STREET 2:** 20TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** 8586920539

**MAIL ADDRESS:**
- **STREET 1:** 545 WEST 25TH STREET
- **STREET 2:** 20TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934.**

**Commission File Number: 001-39935**

**BIOTECH ACQUISITION COMPANY**

**(Exact name of registrant as specified in its charter)**

**545 West 25th Street**

**20th Floor**

**New York, New York 10001**

**(212) 227-1905** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant**

**Class A ordinary shares included as part of the units**

**Redeemable warrants included as part of the units** 

**(Title of each class of securities covered by this Form)**

**None**

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)**

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: 0

Pursuant to the requirements of the Securities Exchange Act of 1934, Biotech Acquisition Company has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Dated: February 14, 2023

---

| | |
|:---|:---|
| BIOTECH ACQUISITION COMPANY | BIOTECH ACQUISITION COMPANY |
| By: | /s/ Michael Shleifer |
| Name: | Michael Shleifer |
| Title: | Chief Executive Officer |

---